Pancreatic Ductal Adenocarcinoma (PDAC) is one of the deadliest forms of cancer, with a five-year survival rate of less than 10%. A major contributor to this high mortality is the lack of effective tools for early detection — the disease is typically diagnosed at an advanced, often inoperable stage. Current diagnostic approaches, including imaging and blood-based biomarkers, lack the sensitivity and specificity required for early and accurate identification of PDAC.

OUR SOLUTION
This novel technology introduces a blood test, RNA-based diagnostic platform that leverages non-coding RNAs (ncRNAs) as highly specific biomarkers for early-stage PDAC. Using Next Generation Sequencing (NGS), advanced bioinformatics, and machine learning algorithms, the research team has identified a unique RNA signature strongly associated with PDAC.
This approach enables:
• Earlier and more accurate detection
• Non-invasive monitoring over time
• Improved clinical decision-making and patient outcomes

APPLICATIONS
• Early Diagnosis of PDAC in high-risk and asymptomatic populations
• Monitoring Disease Progression and treatment response
• Companion Diagnostic Tool in oncology clinical trials
• Potential Expansion to other cancers or disease models using the same analytical framework

INTELLECTUAL PROPERTY
US Provisional PRIORITY 63/749,827